Financial Survey: ADMA Biologics (ADMA) vs. Array BioPharma (ARRY)
ADMA Biologics (NASDAQ: ADMA) and Array BioPharma (NASDAQ:ARRY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.
This table compares ADMA Biologics and Array BioPharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
34.6% of ADMA Biologics shares are owned by institutional investors. Comparatively, 85.4% of Array BioPharma shares are owned by institutional investors. 60.4% of ADMA Biologics shares are owned by insiders. Comparatively, 3.2% of Array BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
ADMA Biologics has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500. Comparatively, Array BioPharma has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500.
Valuation & Earnings
This table compares ADMA Biologics and Array BioPharma’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|ADMA Biologics||$10.66 million||6.65||-$19.51 million||($0.82)||-3.35|
|Array BioPharma||$150.85 million||13.64||-$116.81 million||($0.74)||-14.11|
ADMA Biologics has higher revenue, but lower earnings than Array BioPharma. Array BioPharma is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and recommmendations for ADMA Biologics and Array BioPharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ADMA Biologics presently has a consensus price target of $9.00, suggesting a potential upside of 227.27%. Array BioPharma has a consensus price target of $14.13, suggesting a potential upside of 35.30%. Given ADMA Biologics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe ADMA Biologics is more favorable than Array BioPharma.
ADMA Biologics beats Array BioPharma on 8 of the 13 factors compared between the two stocks.
ADMA Biologics Company Profile
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Array BioPharma Company Profile
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.